ITCI Quantitative Stock Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2025
0mins
Source: NASDAQ.COM
Investment Analysis of INTRA-CELLULAR THERAPIES INC: The stock ITCI is rated 66% using Validea's Quantitative Momentum Investor model, indicating moderate interest based on its strong fundamentals and valuation in the Biotechnology & Drugs industry.
About Wesley Gray: Wesley Gray, founder of Alpha Architect and author of notable investment books, is recognized for his expertise in quantitative investing strategies and has a PhD from the University of Chicago.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
